Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02070965 · ClinicalTrials.gov registry record · Phase 2
DFD01 Spray vs Comp01 Lotion HPA Axis Suppression Study in Patients With Moderate to Severe Plaque Psoriasis
A Phase 2 study, sponsored by Primus Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 75
- Enrollment target
NCT02070965 is a Phase 2 study that has completed, run by Primus Pharmaceuticals. The registered enrollment target is 75 participants.
The verdict
NCT02070965, a Phase 2 study, has completed, sponsored by Primus Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 75 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the potential of DFD01 spray to suppress the HPA (hypothalamic-pituitary-adrenal) axis as compared to Comp01 lotion when applied twice daily for 15 days.
Interventions
- DRUG DFD01 Spray
- DRUG Comp01 Lotion
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 75 participants |
| Start Date | 2014-01 |
| Est. Completion | 2014-10 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02070965
The ClinicalTrials.gov registry entry for NCT02070965 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 75 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Primus Pharmaceuticals, which has 15 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which DFD01 Spray is the first listed.
NCT02070965 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02070965 about?
NCT02070965 is a clinical study titled "DFD01 Spray vs Comp01 Lotion HPA Axis Suppression Study in Patients With Moderate to Severe Plaque Psoriasis". The purpose of this study is to evaluate the potential of DFD01 spray to suppress the HPA (hypothalamic-pituitary-adrenal) axis as compared to Comp01 lotion when applied twice daily for 15 days.
What is the current status of trial NCT02070965?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 75 participants. The study started on 2014-01. Estimated completion is 2014-10.
What interventions are being tested in trial NCT02070965?
The interventions under investigation include: DFD01 Spray (DRUG), Comp01 Lotion (DRUG).
Who is sponsoring clinical trial NCT02070965?
This trial is sponsored by Primus Pharmaceuticals, which has 15 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.